Skip to Content
scroll

CSL Limited (CSL)

ASX.CSL $239.37

20 MINUTE DELAYED

14 DAYS FREE ACCESS

Join Market Matters and get full access
to all our Opinion + Action

LEARN MORE

CSL $239.37

20 MINUTE DELAYED

TODAY

-0.23 %

1 YEAR RETURN

0.00%

VOLUME

807,629

DIV YIELD

1.77%

PE RATIO

26.16

52 WEEK RANGE

228.61

313.55

ANALYSIS

i

SHARE PRICE ACTIVITY
Last (Price)

239.37

Change

-0.56 (-0.23)

Bid / Ask

239.36 - 239.37

Volume

807,629

Turnover

193,740,937

Open

239.20

Day Range

236.90 - 240.43

VWAP

238.14

Prev Close

239.92

Last Trade

09/05 3:40pm (AEST)

i

KEY INFORMATION
Sector

Healthcare

Shares Issued

482,751,160

NTA/Share

0.00

Last Dividend

2.07

Dividend Ex Date

10 MAR 2025

Dividend Pay Date

09 APR 2025

i

BROKER CALLS

current

Mean

1.94

Target Price

0.00

BUY

i

CURRENT ()
Revenue

14,800.00

EBITDA

4,894.00

Profit

2,907.00

Earnings Per Share (EPS)

0

Dividend Per Share (DPS)

0

Yield %

1.77

Market Cap

0

Price to Earnings Ratio (P/E)

26.16

i

TARGET PRICE FORECAST

i

ESTIMATES ()
Revenue

15,696.21

EBITDA

5,263.56

Profit

3,166.79

Earnings Per Share (EPS)

6.49

Dividend Per Share (DPS)

2.92

i

BROKER CONSENSUS RECOMMENDATION

BUY

SELL

Target Price

0.00

Lt Growth Rate

0.00

Recommendation (BUY)

1.94
OPINION
ACTION
image description

Business Summary

CSL Limited (CSL) is a global biotechnology company that develops and delivers innovative medicines that save lives, protect public health and help people with life-threatening medical conditions live full lives. CSL is also involved in research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. CSL's operating model for its two businesses, CSL Behring and Seqirus.

Tagged video
WATCH
image description
Pulse Check Webinar: Opportunities in the unloved parts of the market Recorded Wednesday 27st September
image description

Relevant suggested news and content from the site

image description

Only available to Members

Take a free 14 day Market Matters trial – full access to all our reports, portfolios, positions, buy and sell recommendations. Access the latest views on the latest developments from professional money managers. It's free and no payment details are required
For membership options and pricing. Click here
Back to top